Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 26, 2017

View Archived Issues

Kala Pharmaceuticals submits NDA for Inveltys to FDA

Roche reflects on accomplishments of third quarter 2017

Core lung cancer symptoms improved with dacomitinib in phase III trial

Novel Fc fusion GDF15 molecules for the treatment of obesity

Chugai files an application for additional indication for Perjeta in Japan

Assembly Biosciences presents phase Ia data for ABI-H0731

Zafgen compound ZGN-839 attenuates liver injury in NASH model

Ebola vaccine approved in China

Shionogi files for approval to manufacture and sell S-033188 in Japan

Neurocrine Biosciences begins T-Force GOLD study of Ingrezza in Tourette syndrome

FDA recognizes orphan drug exclusivity for Gocovri for dyskinesia in Parkinson's disease

GlaxoSmithKline patents novel BRD4 inhibitors

Medshine Discovery divulges EZH2 inhibitors

Roche and Genentech present ER-alpha modulators for breast cancer

PTC Therapeutics receives complete response letter for Translarna NDA

Tyme Technologies finds potential method and biomarker that could potentiate calcification of tumors

3R Valo discloses NO production inhibitors

Alopexx Vaccine completes phase I study of AV-0328

Cara Therapeutics doses first patient in study of CR-845

Shanghai Xunhe Pharmaceutical Technology divulges CDK4/6 inhibitors

FDA approves IND transfer of first TriKE, OXS-3550

Evotec and Tesaro announce immuno-oncology drug discovery collaboration

FDA grants fast track designation to Prometic's PBI-4050 for IPF

FREM/FRAS complex found to be behind CDH development

Essential tremor induced in Drosophila via KCNS2 gene overexpression

GSK announces pipeline highlights of third quarter 2017

Pulmocide initiates phase I study of inhaled PC-945

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 24, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026